Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2015; 36(03): 189-192
DOI: 10.4103/0971-5851.166757
CONFERENCE REVIEW

Breast and gastrointestinal cancer updates from ASCO 2015

Shaheenah Dawood
Department of Medical Oncology, Dubai Hospital, Dubai, UAE
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

This review focuses on the updates presented at the ASCO 2015 symposium in breast and gastrointestinal malignancies. Some were practice changing while others gave us an exciting glimpse into what′s to come in the very near future. Immunotherapy was the buzz word this year with data presented on every tumor site. Data on the efficacy of anti PD-1 agents in colorectal, hepatocellular and gastric cancer were presented. In breast cancer we saw data on a new and exciting therapeutic target in the form of androgen receptor among triple receptor negative breast tumors presented. Positive results of the PALOMA 3 trial were presented that has given women with hormone receptor positive metastatic breast cancer another therapeutic option. Furthermore data on strategies to further improve anti her2 therapy, optimizing of chemotherapy in the early and advanced stage and various strategies to improve endocrine therapy among patients with breast cancer were presented.

Keywords

ASCO - breast cancer - colorectal cancer - immunotherapy


Publication History

Article published online:
12 July 2021

© 2015. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Perez EA, Awada A, O′Shaughnessy J, Rugo HS, Twelves C, Im SA, et al. Phase III trial of etirinotecanpegol (EP) versus treatment of physician′s choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study. J Clin Oncol 2015;33. [Suppl; abstr 1001].
  • 2 Yardley DA, Hainsworth JD, Harwin WN, Goble SA, Daniel BR, Ackerman MA, et al. TITAN: Ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): Preliminary toxicity of a Sarah Cannon Research Institute phase III trial. J Clin Oncol 2011;29. [Suppl; abstr 1103].
  • 3 Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow L, et al. Primary results, NRG oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. J Clin Oncol 2015;33. [Suppl; abstr LBA500].
  • 4 Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, et al. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). J Clin Oncol 2015;33. [Suppl; abstr 501].
  • 5 Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209-19.
  • 6 Ellis PA, Barrios CH, Eiermann W, Toi M, Im YH, Conte PF, et al. Phase III, randomized study of trastuzumabemtansine (T-DM1) ± pertuzumab (P) vstrastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. J Clin Oncol 2015;33. [Suppl; abstr 507].
  • 7 Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). J Clin Oncol 2015;33. [Suppl; abstr 508].
  • 8 Miyashita M, Sasano H, Tamaki K, Hirakawa H, Watanabe G, Tada H, et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer. J Clin Oncol 2015;33. [Suppl; abstr 510].
  • 9 Traina TA, Miller K, Yardley DA, O′Shaughnessy J, Cortes J, Awada A, et al. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J Clin Oncol 2015;33. [Suppl; abstr 1003].
  • 10 Le DT, Uram JN, Wang H, Bartlett B, Kemberling H, Eyring A, et al. PD-1 blockade in tumors with mismatch repair deficiency. J Clin Oncol 2015;33. [Suppl; abstr LBA100].
  • 11 El-Khoueiry AB, Melero I, Crocenzi TS, Welling TH, Yau TC, Yeo W, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015;33. [Suppl; abstr LBA101].
  • 12 Bang YJ, Chung HC, Shankaran V, Geva R, Catenacci DV, Gupta S, et al. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol 2015;33. [Suppl; abstr 4001].
  • 13 Yanhong D, Pan C, Lan P, Wang L, Cui L, Chen D, et al. A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC study): Preliminary results. J Clin Oncol 2015;33. [Suppl; abstr 3500].
  • 14 Gibbs P, Volker H, Sharma NK, Findlay MP, Ricke J, Gebski V, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2015;33. [Suppl; abstr 3502].
  • 15 Siena S, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol 2015;33. [Suppl; abstr 3508].